Conn Syndrome with Hyperthyroidism and Refractory Hypokalemia: A Case Report
Keywords:
Conn syndrome, hyperaldosteronism, hypokalemiaAbstract
Conn syndrome is an adrenal gland adenoma that causes primary hyperaldosteronism, with a prevalence of <1% in the world population. Therefore, this case report presents a patient with Conn syndrome co-existing with hyperthyroidism. A 26-year-old female was admitted with muscle spasms in the left arm and muscle weakness in both legs for a day, palpitations, excessive sweating, nocturia, polyuria, and polydipsia. The patient had a history of hyperthyroidism for 10 years and routinely took anti-hypertension (Nifedipine), anti-thyroid, and potassium supplements. Physical examination showed the presence of hypertension. In addition, laboratory examinations revealed hypokalemia, slightly elevated FT4. The patient showed a high level of ARR (Aldosterone-Renin ratio; >30 ng/dL), consistent with primary hyperaldosteronism. Since abdominal USG revealed no abnormality, abdominal MRI with contrast was performed and showed an adenoma in the left adrenal gland. During admission, the patient had refractory hypokalemia despite various efforts to correct the defect. An anti-hypertension drug was then administered, particularly a mineralocorticoid antagonist receptor (Spironolactone). After the treatment, the patient had manageable hypertension and a normal potassium serum level, with no symptoms. Subsequently, discharge was then granted after 9 days of treatment, with a surgery schedule.Conn syndrome with hyperthyroidism can cause refractory hypokalemia, which transforms into a challenge in patient management. With early detection and management, the outcome of this case is manageable.References
Faconti L, Kulkarni S, Delles C, et al. Diagnosis and management of primary hyperaldosteronism in patients with hypertension: a practical approach endorsed by the British and Irish Hypertension Society. J Hum Hypertens. 2024 Jan 1;38(1):8–18.
Shaqran T, Alsuliman A, Alzhrani H, et al. Prevalence, risk factors, and management of Conn's syndrome; A systematic review. International Journal of Medicine in Developing Countries. 2024;487–95.
Orczyk J, Ołownia A, Gałązka JK, Polak A, Matyjaszek-Matuszek B. A nonspecific clinical picture and the course of Conn syndrome — current findings in the screening program for hypertensive patients. Arterial Hypertension (Poland). 2023;27(3):189–92.
Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: Case detection, diagnosis, and treatment: An endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism. 2016 May 1;101(5):1889–916.
Siddikovna TG, Mizrob A, Shaxriddin I, Abbosjon K, Bunyod N, Timur R. Primary hyperaldosteronism [Internet]. Samarkand; 2024. Available from: www.mudarrisziyo.uz
Dogra P, Bancos I, Young WF. Primary aldosteronism: A pragmatic approach to diagnosis and management. Mayo Clinic Proceedings. 2023;98:1207–15.
Hundemer GL, Vaidya A. Primary aldosteronism diagnosis and management: A clinical approach. Endocrinology and Metabolism Clinics of North America. 2019;48:681–700.
Käyser SC, Deinum J, De Grauw WJC, et al. Prevalence of primary aldosteronism in primary care: A cross-sectional study. British Journal of General Practice. 2018 Feb 1;68(667):e114–22.
Hannemann A, Wallaschofski H. Prevalence of primary aldosteronism in patients’ cohorts and in population-based studies - A review of the current literature. Hormone and Metabolic Research. 2012;44:157–62.
Stowasser M, Wolley M, Wu A, et al. Pathogenesis of familial hyperaldosteronism type II: New concepts involving anion channels. Current Hypertension Reports. 2019;21.
Loscalzo J, Kasper DL, Longo DL, Fauci AS, Hauser SL, Jameson JL. Harrison’s principles of internal medicine. Vol. 21. 2022.
Netter FH. Netter atlas of human anatomy. 8th ed. Vol. 1. Philadelphia: Saunders Elsevier; 2014.
Scanlon VC, Sanders T. Essentials of anatomy and physiology. 5th ed. In: Deitch LB, Sorkowitz A, Richman IH, O’Brien C, editors. Vol. 1. Philadelphia: F A Davis Company; 2007. p. 236–42.
Wrenn SM, Vaidya A, Lubitz CC. Primary aldosteronism. Gland Surg. 2020 Feb;9(1):14–24.
Williams TA, Reincke M. Pathophysiology and histopathology of primary aldosteronism. Trends in Endocrinology & Metabolism. 2022 Jan;33(1):36–49.
Yamada K, Tanabe A, Hashimoto M, Ohsugi M, Ueki K, Kajio H. A single-center retrospective study on the clinical features of thyrotoxic periodic paralysis. PLoS One. 2024 Aug 1;19(8):e0308076.
Idham M, Prajitno JH. Management of hypokalemia in patients with thyrotoxicosis periodic paralysis in Soetomo general hospital: A case report. Annals of Medicine & Surgery. 2022 Dec;84.
Payus AO, Liew SL, Tiong N, Mustafa N. Hypokalaemic periodic paralysis secondary to subclinical hyperthyroidism: an uncommon cause of acute muscle paralysis. BMJ Case Rep. 2021 Jun 24;14(6):e240666.
Morera J, Reznik Y. Management of endocrine disease: The role of confirmatory tests in the diagnosis of primary aldosteronism. Eur J Endocrinol. 2019 Feb;180(2): R45–58.
Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: Case detection, diagnosis, and treatment: An endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism. 2016 May 1;101(5):1889–916.
Hung A, Ahmed S, Gupta A, et al. Performance of the aldosterone to renin ratio as a screening test for primary aldosteronism. Journal of Clinical Endocrinology and Metabolism. 2021 Aug 1;106(8):2423–35.
Lee FT, Elaraj D. Evaluation and management of primary hyperaldosteronism. Surgical Clinics of North America. 2019 Aug;99(4):731–45.
Mulatero P, Bertello C, Rossato D, et al. Roles of clinical criteria, computed tomography scan, and adrenal vein sampling in differential diagnosis of primary aldosteronism subtypes. J Clin Endocrinol Metab. 2008 Apr 1;93(4):1366–71.
Miyake Y, Tanaka K, Nishikawa T, et al. Prognosis of primary aldosteronism in Japan: results from a nationwide epidemiological study. Endocr J. 2014;61(1):35–40.
Ho WY, Hsiao CC, Wu PH, et al. Comparison of different medical treatments for primary hyperaldosteronism: a systematic review and network meta-analysis. Ther Adv Chronic Dis. 2024 Jan 19;15.
Meyer A, Brabant G, Behrend M. Long‐term follow‐up after adrenalectomy for primary aldosteronism. World J Surg. 2005 Feb 20;29(2):155–9.
Williams TA, Lenders JWM, Mulatero P, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017 Sep;5(9):689–99.
Simone G, Anceschi U, Tuderti G, et al. Robot-assisted partial adrenalectomy for the treatment of Conn’s syndrome: Surgical technique, and perioperative and functional outcomes. Eur Urol. 2019 May 1;75(5):811–6.
Herd A, Harman R, Taylor E. Surgical outcomes following laparoscopic adrenalectomy for the treatment of Conn’s syndrome (primary hyperaldosteronism) between 1999 and 2006. N Z Med J. 2010 Oct 15;123(1324):50–6.
Iacobone M, Citton M, Viel G, Rossi GP, Nitti D. Approach to the surgical management of primary aldosteronism. Gland Surg [Internet]. 2015 Feb;4(1):69–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25713782
Hundemer GL, Vaidya A. The role of surgical adrenalectomy in primary aldosteronism. European Journal of Endocrinology. 2020; 163:R183–94.
Miller BS. Surgical management of primary aldosteronism. Surgical Clinics of North America. W.B. Saunders; 2024.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Tamara Audrey Kadarusman, Satria Agung Maulana Fahmi, Rusdiyana Ekawati
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright
The authors who publish in this journal agree to the following requirements:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)
Privacy Statement
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.
